Effects of citrate acid concentrate on hemodialysis adequacy, reuse, and quality of life

A prospective randomized crossover trial

S. P. Nagaraju, S. Kosuru, R. Parthasarathy, A. S. Mareddy, R. P. Attur, D. Rangaswamy, S. P. Nagaraju, S. Kaza, S. Shenoy, K. Saraf, S. L.K. Laxminarayana, U. V. Mateti, V. Guddattu

Research output: Contribution to journalArticle

Abstract

We conducted a randomized crossover trial to identify whether the use of citrate dialysate (CD) for bicarbonate hemodialysis is beneficial compared to regular acetate dialysate (AD) in terms of adequacy, reuse, and quality of life. Thirty-two stable end-stage renal disease patients on twice-weekly maintenance hemodialysis were randomly assigned to CD or AD fluid in a single-blinded randomized prospective crossover trial of 1-year duration. The primary outcomes studied were the impact of CD in comparison with AD on hemodialysis adequacy, reuse of dialyzer, and quality of life. Secondary outcomes studied were the effect on intradialytic hypotension, acidosis correction, and episodes of symptomatic hypocalcemia. A total number of 28 patients underwent a total of 1456 sessions of hemodialysis with CD over 6 months and 1456 sessions with AD over 6 months. There was a significant increase in dialyzer reuse with the use of CD (P = 0.02). There was no difference in dialyzer adequacy as measured by Single pool Kt/V (spKt/V) (P = 0.840) and urea reduction ratio (%) (P = 0.90). Quality of life did not differ between the two groups. No statistically significant difference was observed in predialysis arterial pH (P = 0.23) serum bicarbonate (0.17) and calcium change (P = 0.16). CD is safe and equally effective as compared to AD. It significantly improves the reuse of dialyzer but it does not offer any added advantage in terms of improvement in hemodialysis adequacy and quality of care.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalIndian Journal of Nephrology
Volume28
Issue number4
DOIs
Publication statusPublished - 01-07-2018

Fingerprint

Dialysis Solutions
Citric Acid
Cross-Over Studies
Renal Dialysis
Quality of Life
Acids
Acetates
Hypocalcemia
Quality of Health Care
Bicarbonates
Acidosis
Hypotension
Chronic Kidney Failure
Urea
Maintenance

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Nagaraju, S. P. ; Kosuru, S. ; Parthasarathy, R. ; Mareddy, A. S. ; Attur, R. P. ; Rangaswamy, D. ; Nagaraju, S. P. ; Kaza, S. ; Shenoy, S. ; Saraf, K. ; Laxminarayana, S. L.K. ; Mateti, U. V. ; Guddattu, V. / Effects of citrate acid concentrate on hemodialysis adequacy, reuse, and quality of life : A prospective randomized crossover trial. In: Indian Journal of Nephrology. 2018 ; Vol. 28, No. 4. pp. 287-290.
@article{e24e80a684f4418a81297ad1240c72e8,
title = "Effects of citrate acid concentrate on hemodialysis adequacy, reuse, and quality of life: A prospective randomized crossover trial",
abstract = "We conducted a randomized crossover trial to identify whether the use of citrate dialysate (CD) for bicarbonate hemodialysis is beneficial compared to regular acetate dialysate (AD) in terms of adequacy, reuse, and quality of life. Thirty-two stable end-stage renal disease patients on twice-weekly maintenance hemodialysis were randomly assigned to CD or AD fluid in a single-blinded randomized prospective crossover trial of 1-year duration. The primary outcomes studied were the impact of CD in comparison with AD on hemodialysis adequacy, reuse of dialyzer, and quality of life. Secondary outcomes studied were the effect on intradialytic hypotension, acidosis correction, and episodes of symptomatic hypocalcemia. A total number of 28 patients underwent a total of 1456 sessions of hemodialysis with CD over 6 months and 1456 sessions with AD over 6 months. There was a significant increase in dialyzer reuse with the use of CD (P = 0.02). There was no difference in dialyzer adequacy as measured by Single pool Kt/V (spKt/V) (P = 0.840) and urea reduction ratio ({\%}) (P = 0.90). Quality of life did not differ between the two groups. No statistically significant difference was observed in predialysis arterial pH (P = 0.23) serum bicarbonate (0.17) and calcium change (P = 0.16). CD is safe and equally effective as compared to AD. It significantly improves the reuse of dialyzer but it does not offer any added advantage in terms of improvement in hemodialysis adequacy and quality of care.",
author = "Nagaraju, {S. P.} and S. Kosuru and R. Parthasarathy and Mareddy, {A. S.} and Attur, {R. P.} and D. Rangaswamy and Nagaraju, {S. P.} and S. Kaza and S. Shenoy and K. Saraf and Laxminarayana, {S. L.K.} and Mateti, {U. V.} and V. Guddattu",
year = "2018",
month = "7",
day = "1",
doi = "10.4103/ijn.IJN_154_17",
language = "English",
volume = "28",
pages = "287--290",
journal = "Indian Journal of Nephrology",
issn = "0971-4065",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

Effects of citrate acid concentrate on hemodialysis adequacy, reuse, and quality of life : A prospective randomized crossover trial. / Nagaraju, S. P.; Kosuru, S.; Parthasarathy, R.; Mareddy, A. S.; Attur, R. P.; Rangaswamy, D.; Nagaraju, S. P.; Kaza, S.; Shenoy, S.; Saraf, K.; Laxminarayana, S. L.K.; Mateti, U. V.; Guddattu, V.

In: Indian Journal of Nephrology, Vol. 28, No. 4, 01.07.2018, p. 287-290.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of citrate acid concentrate on hemodialysis adequacy, reuse, and quality of life

T2 - A prospective randomized crossover trial

AU - Nagaraju, S. P.

AU - Kosuru, S.

AU - Parthasarathy, R.

AU - Mareddy, A. S.

AU - Attur, R. P.

AU - Rangaswamy, D.

AU - Nagaraju, S. P.

AU - Kaza, S.

AU - Shenoy, S.

AU - Saraf, K.

AU - Laxminarayana, S. L.K.

AU - Mateti, U. V.

AU - Guddattu, V.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We conducted a randomized crossover trial to identify whether the use of citrate dialysate (CD) for bicarbonate hemodialysis is beneficial compared to regular acetate dialysate (AD) in terms of adequacy, reuse, and quality of life. Thirty-two stable end-stage renal disease patients on twice-weekly maintenance hemodialysis were randomly assigned to CD or AD fluid in a single-blinded randomized prospective crossover trial of 1-year duration. The primary outcomes studied were the impact of CD in comparison with AD on hemodialysis adequacy, reuse of dialyzer, and quality of life. Secondary outcomes studied were the effect on intradialytic hypotension, acidosis correction, and episodes of symptomatic hypocalcemia. A total number of 28 patients underwent a total of 1456 sessions of hemodialysis with CD over 6 months and 1456 sessions with AD over 6 months. There was a significant increase in dialyzer reuse with the use of CD (P = 0.02). There was no difference in dialyzer adequacy as measured by Single pool Kt/V (spKt/V) (P = 0.840) and urea reduction ratio (%) (P = 0.90). Quality of life did not differ between the two groups. No statistically significant difference was observed in predialysis arterial pH (P = 0.23) serum bicarbonate (0.17) and calcium change (P = 0.16). CD is safe and equally effective as compared to AD. It significantly improves the reuse of dialyzer but it does not offer any added advantage in terms of improvement in hemodialysis adequacy and quality of care.

AB - We conducted a randomized crossover trial to identify whether the use of citrate dialysate (CD) for bicarbonate hemodialysis is beneficial compared to regular acetate dialysate (AD) in terms of adequacy, reuse, and quality of life. Thirty-two stable end-stage renal disease patients on twice-weekly maintenance hemodialysis were randomly assigned to CD or AD fluid in a single-blinded randomized prospective crossover trial of 1-year duration. The primary outcomes studied were the impact of CD in comparison with AD on hemodialysis adequacy, reuse of dialyzer, and quality of life. Secondary outcomes studied were the effect on intradialytic hypotension, acidosis correction, and episodes of symptomatic hypocalcemia. A total number of 28 patients underwent a total of 1456 sessions of hemodialysis with CD over 6 months and 1456 sessions with AD over 6 months. There was a significant increase in dialyzer reuse with the use of CD (P = 0.02). There was no difference in dialyzer adequacy as measured by Single pool Kt/V (spKt/V) (P = 0.840) and urea reduction ratio (%) (P = 0.90). Quality of life did not differ between the two groups. No statistically significant difference was observed in predialysis arterial pH (P = 0.23) serum bicarbonate (0.17) and calcium change (P = 0.16). CD is safe and equally effective as compared to AD. It significantly improves the reuse of dialyzer but it does not offer any added advantage in terms of improvement in hemodialysis adequacy and quality of care.

UR - http://www.scopus.com/inward/record.url?scp=85051779794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051779794&partnerID=8YFLogxK

U2 - 10.4103/ijn.IJN_154_17

DO - 10.4103/ijn.IJN_154_17

M3 - Article

VL - 28

SP - 287

EP - 290

JO - Indian Journal of Nephrology

JF - Indian Journal of Nephrology

SN - 0971-4065

IS - 4

ER -